WO2012077024A1 - Composition for inhibiting the growth of mammalian hair - Google Patents
Composition for inhibiting the growth of mammalian hair Download PDFInfo
- Publication number
- WO2012077024A1 WO2012077024A1 PCT/IB2011/055431 IB2011055431W WO2012077024A1 WO 2012077024 A1 WO2012077024 A1 WO 2012077024A1 IB 2011055431 W IB2011055431 W IB 2011055431W WO 2012077024 A1 WO2012077024 A1 WO 2012077024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibiting
- composition
- hair
- hair growth
- growth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 25
- 210000004209 hair Anatomy 0.000 title claims abstract description 15
- 230000012010 growth Effects 0.000 title claims abstract description 5
- 230000003779 hair growth Effects 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims description 17
- 239000002502 liposome Substances 0.000 claims description 16
- 235000004443 Ricinus communis Nutrition 0.000 claims description 12
- 240000000528 Ricinus communis Species 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- -1 DOPE Chemical compound 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 abstract description 10
- 210000004919 hair shaft Anatomy 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000006071 cream Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000004018 waxing Methods 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150018711 AASS gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
Definitions
- compositions for inhibiting mammalian hair growth are provided.
- the invention relates to inhibiting hair growth.
- the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damages the hair follicle , thereby disabling it to form a normal hair shaft.
- Castor bean is well known for its lipid constituent, castor oil and its medicinal properties especially as a purgative.
- composition for specifically inhibiting mammalian hair growth is a novel invention and would offer an inexpensive method for inhibiting mammalian hair growth.
- the object of this invention is to provide for a composition for inhibiting mammalian hair growth.
- Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from castor beans.
- Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from follicular delivery of aqueous extract of castor beans.
- Another object of this invention is to provide for a composition using vesicular carriers which deliver the active i.e. Rein in the extract directly to the hair follicle without causing allergic reaction.
- Another object of this invention is to provide for a cytotoxic lectin (e.g. Rein) composition using vesicular carriers for hair growth inhibition wherein purification of cytotoxic lectin (e.g. Rein) is not necessary.
- cytotoxic lectin e.g. Rein
- Another object of this invention is to provide the composition in the form of a paste, cream or gel which is easy to apply, has aesthetic appeal and has good spread ability.
- Another object of this invention is to provide for a composition in the form of a paste, cream or gel that leaves no stains on application and isfree of preservatives.
- Another object of this invention is to provide for a composition which could be packed conveniently in jars or tubes.
- the invention relates to inhibiting hair growth.
- the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damages the hair follicle, thereby disabling it to form a normal hair shaft.
- the present invention comprises of compositions for topical application for inhibiting unwanted mammalian hair growth by applying an effective amount of the composition to the skin of individuals in need to inhibit hair, including facial areas, legs, arms, armpits, and torso; irrespective of gender of the subject.
- the composition comprises of a hair-growth- inhibiting active agent dispersed in a dermatologically acceptable vehicle such as but not limiting to oil in water emulsion, gels, sustained release polymer films, sprays, soaps etc.
- vesicular carriers like liposomes can be used for the selective follicular delivery of the hair-growth-inhibiting agent.
- Rein which represents the type II ribosome inactivating proteins, is the active ingredient in the castor bean that inactivates the hair follicle disabling it to form the hair shaft.
- Rein Apart from ricin & its isomers, there is a group of allergens that are present in the castor bean. Rein is water-soluble in nature, but also is present in castor oil in low concentrations. So, both aqueous extract and oil fraction can be used together or separately for the hair-growth inhibition. However, the allergic fraction causes both immediate and delayed hypersensitivity reactions. So, it calls for the treatment of the extract to remove the allergens.
- Various extraction and purification procedures of the herbal extract are well known to those skilled in the art.
- the present invention describes an innovative solution wherein castor bean extract, without purifying Rein, can be used by encapsulating in a carrier like liposome, neosome or microspheres. Use of such vesicular carriers results in delivery of the active i.e. Rein in the extract directly to the hair follicle without causing allergic reaction.
- the hair is removed from the follicle e.g. by waxing or plucking or alternatively by other methods like shaving, depilation.
- Methods of hair removal which remove the hair from the follicle are known to initiate anagen, the growth phase of the hair cycle and also it exposes the hair follicle assembly responsible for the synthesis of hair shaft to the action of the composition herein described.
- the topical compositions are the formulations containing therapeutically effective amounts of the respective active agent and pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as but not limiting to pH adjusting and buffering agents, toxicity adjusting agents and the like, vesicular carriers like liposomes, microspheres, neosomes for carrying the active agent to the hair follicle, along with the usual components of the particular carrier like e.g. for oil in water emulsion, stearic acid and its derivatives, cetyl alcohol and its derivatives, mineral oils, citric acid, preservatives, fragrance, colours etc. or other such topical compositions as described in different pharmaceutical publications, resulting in aesthetically pleasing and easy to use formulations.
- auxiliary substances such as but not limiting to pH adjusting and buffering agents, toxicity adjusting agents and the like, vesicular carriers like liposomes, microspheres, neosomes for carrying the active agent to the hair follicle, along with the usual components of the particular carrier like
- compositions Crude aqueous extracts of castor beans are used for liposome formulations.
- NNuummbbeerr ooff ggeell aanndd ooiill iinn wwaatteerr eemmui.lsions were prepared using varying concentrations of the lliippoossoommee ssuussppeennssiioonn ffoorr aanniimmaall aass wwell as human experiments.
- Oil in water emulsion Mineral oil 26% Cety I alcohol 0.52% 9 ear ic acid 0.94% Get ost eary I al cohol 0.94 %
- Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by ethanol injection method.
- Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by cent rifugat ion.
- Liposomes were prepared using Phospholipon 90 G (Lipoid) 15 mg by thin film formation method and hydrated with the extract (15 ml). Un-encapsulated extract is removed by cent rifugat ion.
- Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by cent rifugat ion.
- Liposomes were prepared using &ya lecithin (Himedia) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by cent rifugat ion.
- Himedia &ya lecithin
- Liposomes were prepared using Soya lecithin (Himedia) 9 mg and DOPE 1 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.
- Liposomes were prepared using Soya lecithin (Himedia) 8 mg and DOPE 2 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011340160A AU2011340160B2 (en) | 2010-12-08 | 2011-12-02 | Composition for inhibiting the growth of mammalian hair |
GB1311617.3A GB2499769B (en) | 2010-12-08 | 2011-12-02 | Composition for inhibiting mammalian hair growth |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1738MU2010 | 2010-12-08 | ||
IN1738/MUM/2010 | 2010-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012077024A1 true WO2012077024A1 (en) | 2012-06-14 |
Family
ID=46206659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/055431 WO2012077024A1 (en) | 2010-12-08 | 2011-12-02 | Composition for inhibiting the growth of mammalian hair |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2011340160B2 (en) |
GB (1) | GB2499769B (en) |
WO (1) | WO2012077024A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084470A1 (en) * | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
US20050085440A1 (en) * | 2002-03-19 | 2005-04-21 | Birch Philip J. | Formulation |
US20060034952A1 (en) * | 2004-08-13 | 2006-02-16 | Kondhalkar Mrinmayee B | Agent for inhibiting the growth of mammalian hair |
US20060257509A1 (en) * | 2003-10-10 | 2006-11-16 | Zimmerman Amy C | Cosmetic composition and methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827510A (en) * | 1997-09-29 | 1998-10-27 | Mesquitta; Trevor E. | Hair growth preparation |
WO2000000002A2 (en) * | 1998-06-09 | 2000-01-06 | Massachusetts Institute Of Technology | Method for current sharing in a superconducting current lead |
-
2011
- 2011-12-02 WO PCT/IB2011/055431 patent/WO2012077024A1/en active Application Filing
- 2011-12-02 AU AU2011340160A patent/AU2011340160B2/en not_active Ceased
- 2011-12-02 GB GB1311617.3A patent/GB2499769B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085440A1 (en) * | 2002-03-19 | 2005-04-21 | Birch Philip J. | Formulation |
US20060257509A1 (en) * | 2003-10-10 | 2006-11-16 | Zimmerman Amy C | Cosmetic composition and methods |
US20050084470A1 (en) * | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
US20060034952A1 (en) * | 2004-08-13 | 2006-02-16 | Kondhalkar Mrinmayee B | Agent for inhibiting the growth of mammalian hair |
US20080145330A1 (en) * | 2004-08-13 | 2008-06-19 | Mrinmayee Bhushan Kondhalkar | Agent for inhibiting the growth of mammalian hair |
Also Published As
Publication number | Publication date |
---|---|
GB2499769B (en) | 2018-04-18 |
GB201311617D0 (en) | 2013-08-14 |
AU2011340160B2 (en) | 2017-10-12 |
AU2011340160A1 (en) | 2013-07-18 |
GB2499769A (en) | 2013-08-28 |
GB2499769A8 (en) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1614430B1 (en) | Compositions containing anti-acne agents and the use thereof | |
DE69627988T3 (en) | INHIBITORS OF NO SYNTHASE | |
US8318678B2 (en) | Cosmetic compositions | |
ES2299483T3 (en) | EXTRACT OF A VEGETAL OF THE EUROPEAN OLEA SPECIES AS AN INHIBITOR OF NON-SYNTHEASE AND ITS USES. | |
ES2209080T3 (en) | ROSACE EXTRACT AS AN BRADIQUININE ANTAGONIST. | |
US8512768B2 (en) | Pain relieving composition | |
JP2005047910A (en) | Sebum secretion-inhibiting composition | |
WO2015147137A1 (en) | Ceramide-formulated external agent composition | |
KR20160143793A (en) | Compositions and methods for reducing oxidative stress | |
AU2011340160B2 (en) | Composition for inhibiting the growth of mammalian hair | |
JP4887050B2 (en) | Inadequate keratinization inhibitor, pore reducing agent | |
JP2002505273A5 (en) | ||
US20060009499A1 (en) | Compositions useful for the treatment of follicular diseases | |
KR20160146779A (en) | Topical compositions for stimulating adipogenesis and lipogenesis to reduce the signs of sking agning | |
RU2170570C1 (en) | Composition for hair washing | |
JPH09255551A (en) | Skin preparation for external use | |
US20060008537A1 (en) | Method of treating acne | |
JPH0971513A (en) | Hair tonic | |
KR20150050982A (en) | Cosmetic composition and external composition comprising acylated saponin for anti-inflammatory | |
Mukherjee et al. | Nonionic surfactant nanovesicles for cosmeceutical applications | |
JPH1192353A (en) | Skin preparation for external use for inhibiting sebum synthesis | |
WO2005099682A1 (en) | Preparations for external use | |
JP3193617B2 (en) | Refreshing agent and composition for human body | |
JP2018016575A (en) | Trpm8 activator, cooling sensation agent, cosmetic, and oral composition | |
AU2011242139B2 (en) | Compositions containing anti-acne agents and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11846088 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 1311617 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20111202 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1311617.3 Country of ref document: GB |
|
ENP | Entry into the national phase |
Ref document number: 2011340160 Country of ref document: AU Date of ref document: 20111202 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11846088 Country of ref document: EP Kind code of ref document: A1 |